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Abstract
Summary The aim of this study was to determine whether
feedback by pharmacists to prescribers of patients eligible for
glucocorticoid-induced osteoporosis prophylaxis would
stimulate the prescribing of osteoporosis prophylaxis. The
intervention did not significantly increase the prescribing of
bisphosphonates in the total study population, but a significant
increase was seen in men and in the elderly. However, the
proportion of bisphosphonate-treated patients remained low.
Introduction The aim of this study was to determine whether
feedback by pharmacists to prescribers of patients eligible for
glucocorticoid-induced osteoporosis prophylaxis (GIOP) would
stimulate the implementation of the Dutch GIOP guideline.
Methods This randomised controlled trial included 695
patients who were dispensed ≥675 mg prednisone equivalents
without a concomitant bisphosphonate prescription within
6 months before baseline. Pharmacists were asked to contact
the physicians of GIOP-eligible patients in the intervention
group to suggest osteoporosis prophylaxis. The primary
endpoint was a bisphosphonate prescription. Secondary
endpoints were a prescription of calcium supplements, vitamin
D or any prophylactic osteoporosis drug (bisphosphonate,
calcium supplements, vitamin D).
Results The group assigned to the intervention was slightly
younger than the control group (68.7±15.4 vs. 65.9±
16.9 years, p =0.02) and used hydrocortisone more often
(7.0 % vs. 3.1 %, p =0.02). Within 6 months, the intervention
did not significantly increase the prescribing of
bisphosphonates (11.4 % after intervention vs. 8.0 % for
controls; hazard ratio [HR] 1.47, 95 % confidence interval
[CI] 0.91–2.39). However, subgroup analyses showed a
significant increase for the primary endpoint in men (12.8 %
vs. 5.1%,HR 2.53, 95%CI 1.11–5.74) and patients ≥70 years
(13.4 % vs. 4.9 %, HR 2.88, 95 % CI 1.33–6.23). The
prescribing of calcium and vitamin D was not significantly
altered.
Conclusion This study showed that active identification of
patients eligible for GIOP by pharmacists did not significantly
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increase the prescribing of bisphosphonates in the total study
population, but there was an increase in men and the elderly.
However, the proportion of GIOP-treated patients remained
low.
Keywords Glucocorticoid-induced osteoporosis .
Intervention . Pharmacist . Physician
Introduction
The use of glucocorticoids, even in low doses, is associated
with rapid bone loss and an increased risk of fractures [1–4].
Bisphosphonates have been shown to be the most effective
drugs for glucocorticoid-induced osteoporosis prophylaxis
(GIOP) [5, 6] and are therefore recommended in
(inter)national guidelines for management of GIOP [7–9].
The most important recommendation in the Dutch guideline
is to consider starting bisphosphonates in post-menopausal
women and men over 70 years who are expected to be treated
with >7.5 mg prednisone (equivalents) per day for at least
3 months. In addition, all other patients who are expected to
use >15 mg prednisone (equivalents) for more than 3 months
should be treated with bisphosphonates. Although the
awareness of the importance of osteoporosis prophylaxis
seems to have increased [10], the widespread implementation
of guidelines remains difficult. Audits have shown that only
10–60 % of patients who are eligible for GIOP receive
appropriate treatment [11–14]. Previous intervention trials that
aimed to increase GIOP were mostly conducted by training of
physicians (general practitioners and rheumatologists) and
frequently included education of patients at risk of GIOP
[15–18]. Unfortunately, these attempts have yielded limited
success.
Until now, a limited number of studies have determined the
impact of pharmacy-based interventions with regard to GIOP
[15, 19]. In the Dutch health care system, pharmacists share a
responsibility with prescribers to properly inform patients on
the advantages and disadvantages of pharmacotherapy and to
assist physicians in this respect. Therefore, pharmacists could
play an important role in the implementation of guidelines for
management of GIOP. The previously conducted studies that
used a pharmacy-based approach for the improvement of
GIOP have shown a significant increase in the prescribing
rates of prophylactic osteoporosis drugs. However, these
studies were limited by a lack of randomisation [15] and a
lack of power [19]. Therefore, the aim of this randomised
controlled trial was to determine whether feedback by
community pharmacists to physicians of patients eligible for
GIOP would stimulate the implementation of the Dutch GIOP
guideline.
Materials and methods
Study participants and setting
This randomised controlled trial was conducted at 29
pharmacies from different parts in the Netherlands.
Pharmacists were invited to participate in the study by a short
announcement in the Dutch Pharmacy Journal. The
pharmacies were located all over the Netherlands. There was
no particular chain of pharmacies involved.
At each participating pharmacy, drug dispensing data from
all patients were collected at baseline (date of first data
extraction, January 2005 to May 2005). We selected all
patients who were dispensed ≥675 mg prednisone equivalents
(≥67.5 defined daily dosages [DDDs] [7, 8]) without a
concomitant bisphosphonate prescription within the 180 days
before baseline and with at least one prescription for a
glucocorticoid within the 90 days before baseline. In the
Netherlands, the vast majority of the population obtains their
medication from only one community pharmacy, enabling the
collection of longitudinal medication histories [20].
Medication records of patients were pseudonymised and were
sent to the researchers. We have excluded patients who had
less than 6 months of medication records before baseline.
Intervention
Block randomisation (using the survey select procedure of SAS,
version 8.2) was performed. After the randomisation, the
pharmacists received feedback on patients who were assigned
to the intervention group. They received a letter with the Dutch
GIOP guideline [8] and a list on paper with all the eligible
patients. Pharmacists were expected to forward the patients on
this list to their own general practitioners and to suggest the
start of osteoporosis prophylaxis (a bisphosphonate). It was
left at the disposal of the individual pharmacist how to
communicate with the general practitioner.
At the end of 6 months of follow-up, additional pharmacy
dispensing records of all patients in the intervention and control
group (usual care) were retrieved. These medication records
were reviewed for the dispensing of bisphosphonates, calcium
supplements and vitamin D during the follow-up period. After
the study period, pharmacists received comparable information
on patients who were originally assigned to the control group.
This study was not covered by the Medical Research
Involving Human Subjects Act (WMO) since the patients
were not directly exposed to the intervention, and approval
by an ethical committee was not required.
Outcome measurements
All patients were followed up from baseline until the start of
osteoporosis prophylaxis or the end of the study period (the
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date of second data extraction), whichever came first. The
primary endpoint was a dispensing of a bisphosphonate.
Secondary endpoints were the dispensing of other
prophylactic osteoporosis drugs (calcium supplements or
vitamin D) and a dispensing of any prophylactic osteoporosis
drug as a composite endpoint (bisphosphonate, calcium
supplements or vitamin D, only the first event was counted).
Statistical analyses
We assumed an event rate of 10 % in the control group over
6 months and an increase to 20 % in the intervention group
[18, 21]. With a two-sided alpha of 0.05 and 90 % power, a
total sample size of 584 patients was estimated which was
increased to 695 patients.
Chi-square tests or Fisher's exact tests were used to
determine baseline differences between the comparison
groups for categorical variables and independent sample t
tests for continuous variables (p <0.05). Cox proportional
hazard models were used to estimate hazard ratios (HRs) for
the start of osteoporosis prophylaxis during the follow-up
period by comparing the intervention group to the control
group. Hazard ratios were adjusted for covariates that were
unevenly distributed between the intervention group and
control group (p <0.05). Patients who did not receive any
prescription of glucocorticoids during the follow-up period
were censored at 1 day after baseline.
In subgroup analyses, results were stratified by gender, the
number of prednisone equivalents (DDDs) received in the
6 months before baseline (67.5–134, 135–270, >270) and
age categories (≤70, >70 years) for the primary and composite
endpoint.
Finally, a Kaplan–Meier plot was used to visualize the time
to start of bisphosphonate use after baseline and the proportion
of patients being newly treated for GIOP during the study
period. This plot was stratified by the randomised
intervention.
All analyses were performed using SAS, version 9.1.
Results
During the first data extraction period, 735 patients were
selected from the participating pharmacies. Of these patients,
31 (4.2 %) were not eligible for bisphosphonate prophylaxis
according to the Dutch guideline. These patients were either
females younger than 50 years or males younger than 70 years
using less than 1,350 mg (135 DDDs) prednisone equivalents,
or females older than 50 or males older than 70 using less than
675 mg (67.5 DDDs) prednisone equivalents. Moreover, nine
Patients who received prescriptions for glucocorticoids in 
the 180 days before baseline with at least 1 prescription 
during the 90 days before baseline without a concomitant 
prescription for a bisphosphonate (n=735)
Exclusion:
-Females <50 or males< 70 dispensed <1350 mg 
prednisone equivalents (N=12)
-Patients with < 6 months medication record 
before start of follow-up (n=9)
-Females>50 or males>70 dispensed <675mg 
prednisone equivalents (n=19)
Analysed (n=343)











No prescriptions during 
follow-up:
n=72 (20.5%)
Fig. 1 Flow chart of the study
procedure
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patients (1.2%) were excluded as they had medication records
available for less than 6 months prior to the first extraction
date. Overall, 695 patients could be randomised, with 343
allocated to the intervention group and 352 to the control
group. During the follow-up period, 38 (11.1 %) patients
who were allocated to the intervention group and 36
(10.2 %) patients in the control group did not receive any
new glucocorticoid prescription but did collect prescriptions
for other drugs. Furthermore, 63 (18.4 %) patients in the
intervention group and 72 (20.5 %) patients in the control
group did not collect any prescription during follow-up
(Fig. 1).
The group assigned to the intervention was slightly younger
than the control group (65.9±16.9 vs. 68.7±15.4 years, p =
0.02) and used hydrocortisone more often in the 6 months
before baseline (7.0 % vs. 3.1 %, p =0.02). All other baseline
characteristics and mean follow-up time were similar between
the intervention and the control group (Table 1).
During a mean follow-up period of 6.2 months, the
primary endpoint (a prescription for a bisphosphonate
during follow-up) was achieved by 39 patients (11.4 %)
in the intervention group and by 28 patients (8.0 %) in
the control group. Figure 2 shows the time to initiation of
a bisphosphonate for both study groups. The intervention
did not significantly increase the prescribing rate of
bisphosphonates when compared to the control group
(unadjusted HR 1.47, 95 % confidence interval [CI]
0.91–2.39). This effect changed marginally after
adjustment for age and use of hydrocortisone in the
6 months before baseline (Table 2). However, subgroup
analyses showed that the prescribing rate of bisphosphonates
was significantly increased in the intervention group for male
patients (12.8 % vs. 5.1 %; unadjusted HR 2.53, 95 % CI
1.11–5.74; adjusted HR 2.55, 95 % CI 1.12–5.80) and for
patients older than 70 years (13.4 % vs. 4.9 %; unadjusted HR
2.88, 95 % CI 1.33–6.23; adjusted HR 2.99, 95 % CI 1.38–
6.47). The received cumulative number of DDD prednisone
equivalents in the 6 months before baseline did not change the
effect of the intervention. Similar results were seen for the
composite endpoint of any prophylactic osteoporosis drug
(Table 3).
Discussion
This randomised controlled trial showed that active
identification of GIOP-eligible patients by community
pharmacists did not significantly increase the prescribing rate
of bisphosphonates in the total study population. However,
subgroup analyses showed that there was a significant
increase in the primary endpoint in males and in the elderly
(>70 years). Similar results were seen for the composite
endpoint of any prophylactic osteoporosis drug
(bisphosphonate, calcium, or vitamin D).
To the best of our knowledge, this is the first randomised
controlled trial where pharmacists identified GIOP-eligible
patients and subsequently contacted the prescriber, without
further training of the patient or the physician [22]. The only
previously conducted pharmacy-based randomised controlled








Follow-up (mean±SD months) 6.2±1.1 6.2±1.1 NS
Female 55.4 % 54.5 % NS
Age (mean±SD years) 68.7±15.4 65.9±16.9 0.02
Age categories
<50 years 11.6 % 18.4 % 0.01
50–70 years 36.1 % 31.5 % NS
>70 years 52.3 % 50.1 % NS
Type of glucocorticoid in the 6 months before baselinea
Betamethasone 1.4 % 0.3 % NS
Cortisone acetate 3.1 % 4.4 % NS
Dexamethasone 7.9 % 6.1 % NS
Fludrocortisone 2.0 % 2.9 % NS
Hydrocortisone 3.1 % 7.0 % 0.02
Methylprednisolone 0.3 % 0.3 % NS
Prednisolone 17.2 % 17.2 % NS
Prednisone 79.3 % 75.5 % NS
Triamcinolone 1.7 % 1.5 % NS
Cumulative DDDs of
prednisone equivalents in








<135 DDDs 41.2 % 37.9 % NS
135–270 DDDs 44.6 % 50.7 % NS
>270 DDDs 14.2 % 11.4 % NS
Co-medication in the 6 months prior to baseline
Opioid analgesics 6.2 % 7.0 % NS
Cytostatic drugs 5.7 % 3.8 % NS
Anti-emetic drugs 4.5 % 2.9 % NS
Calcium 16.7 % 16.6 % NS
Vitamin D 6.0 % 7.0 % NS
HRT or SERMs 0.9 % 2.0 % NS
Anti-ulcer drugs 43.6 % 44.3 % NS
Bisphosphonate use >6 months
prior to baseline
12.2 % 10.8 % NS
Comparison of baseline characteristics between groups was significant at
p <0.05
HRT hormone replacement therapy, SERM selective estrogen receptor
modulator, SD standard deviation, DDD defined daily dosage.
a Use of more than one type of glucocorticoids per patient is possible
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trial that aimed to increase GIOP found an increased
prescribing rate of calcium but not of bisphosphonates [19].
This trial was conducted at 15 community pharmacies
(intervention 70 patients, control 26 patients). The
pharmacists received training for GIOP, identified eligible
patients, gave them education for GIOP and contacted the
prescriber when necessary. However, pharmacists in both the
intervention and control groups received training about GIOP
and the importance of bone mineral density (BMD) testing
which may have diluted the results. Another randomised
controlled trial has shown a twofold increase (28 patients
(22 %) intervention group vs. 14 patients (11 %) control
group; relative risk 2.1, 95 % CI 1.1–3.7) in the composite
endpoint of BMD testing or incident osteoporosis treatment
with a community pharmacist screening programme [21]. In
contrast to the present study, all patients and pharmacists
received education about osteoporosis. Other attempts to
increase GIOP mostly included educational interventions
directed at physicians (general practi t ioners or
rheumatologists) but were often without or with modest
results [16–18].
The lack of an overall intervention effect was accompanied
by a low number of bisphosphonate-treated patients [14, 17].
It should be noted that the study population did not include
patients who already received a prescription for a
bisphosphonate in the 6 months prior to baseline. Chitre et al.
(2008) similarly excluded these patients and found comparable
incident treatment rates for osteoporosis prophylaxis. In
addition, our study population included patients who received
a bisphosphonate more than 6 months before baseline (10.8 %
in the intervention group, 12.2 % in the control group). These
patients could have had earlier adverse effects for
bisphosphonates or had other reasons for discontinuing these
drugs. Moreover, not all patients still used glucocorticoids
during follow-up or tapered off the dose, and as a result,
GIOP prophylaxis was no longer required.
In the control group, the proportion of GIOP-treated males
was twofold lower as compared to females. The neglecting of
osteoporosis prophylaxis in males is in line with other studies
[11, 14, 23]. The difference in the intervention effect between
males and females may be explained by this phenomenon;
prescribers may have been more likely to have previously
Fig. 2 Incident bisphosphonate
use in the intervention group
(black line) and control group
(grey line)
Table 2 Start of osteoporosis prophylaxis drugs after intervention, as compared to usual care
Treatment Start OP intervention (%) Start OP control (%) Unadjusted HR (95 % CI) Adjusted HR (95 % CI)a
Bisphosphonate 11.4 8.0 1.47 (0.91–2.39) 1.54 (0.95–2.50)
Calcium 5.3 2.6 2.06 (0.93–4.59) 2.12 (0.95–4.72)
Vitamin D 3.5 1.7 2.05 (0.77–5.47) 2.08 (0.78–5.55)
Bisphosphonate, calcium or vitamin D 13.4 9.4 1.48 (0.94–2.31) 1.53 (0.98–2.39)
OP osteoporosis prophylaxis drugs, HR hazard ratio, CI confidence interval
a Adjusted for age categories (≤70, >70) and use of hydrocortisone in the 6 months before baseline
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considered osteoporosis prophylaxis in females. The low
prescribing rate in the elderly may be explained by the initial
belief of physicians that extra treatment with bisphosphonates
would be inappropriate due to the presence of multiple co-
morbidities or a large number of medicines. On the other
hand, elderly patients do have a higher absolute fracture risk
and the consequences of fractures (especially for those of the
hip) can be tremendous [24]. The increased prescribing of
bisphosphonates for elderly in the intervention group may be
explained by an increased awareness for this fact. It should,
however, be noted that the power of this study was not
calculated specifically for these subgroup analyses.
Strengths of this study include its size and the simple set-up
of the intervention. In contrast to previous trials, patients and
physicians were not educated for GIOP and pharmacists only
received the recent guideline without further training [19, 21].
This study is therefore a better reflection of the real-life
situation. The identification of patients at risk for GIOP can
easily be integrated in the tasks of the pharmacists and is not
labour intensive or costly when compared to interventions
involving education of physicians and/or patients [25].
However, the lack of an overall significant increase in the
number of bisphosphonate-treated patients calls for additional
measures. The intervention in its present from can be
combined with interdisciplinary meetings between
pharmacists and general practitioners beforehand and after
follow-up, which include feedback about current prescribing
and differences between practices. This approach is not very
costly and is achievable in daily practice. In addition, clinical
rules are currently implemented, and this would make it even
easier to extract GIOP-eligible patients from pharmacy
information systems. Indeed, a large randomised controlled
trial (RCT) showed the significant benefit of a more intensive,
pharmacist-led intervention in reducing the number of
prescribing errors [26]. Pharmacists did not only give
feedback to physicians about medication errors during
meetings, but also reviewed medical records and invited the
patients.
Table 3 Start of osteoporosis prophylaxis drugs after intervention, as compared to usual care, stratified by gender, cumulative dosage prednisone
equivalents and age categories
Start OP intervention (%) Start OP control (%) Unadjusted HR (95 % CI) Adjusted HR (95 % CI)a
Bisphosphonate
Overall 11.4 8.0 1.47 (0.91–2.39) 1.54 (0.95–2.50)
Stratified by gender
Men 12.8 5.1 2.53 (1.11–5.74) 2.55 (1.12–5.80)
Women 10.2 10.3 1.03 (0.55–1.93) 1.10 (0.58–2.06)
Stratified by cumulative dosage prednisone equivalents within 6 months before baseline
67.5–134 DDDs 10.8 7.6 1.52 (0.69–3.36) 1.54 (0.70–3.38)
135–270 DDDs 10.9 6.4 1.65 (0.77–3.56) 1.67 (0.77–3.59)
>270 DDDs 15.4 14.0 1.48 (0.50–4.41) 1.47 (0.49–4.38)
Stratified by age categoryb
≤70 years 9.4 11.3 0.84 (0.43–1.63) 0.89 (0.46–1.73)
>70 years 13.4 4.9 2.88 (1.33–6.23) 2.99 (1.38–6.47)
Bisphosphonate, calcium or vitamin D
Overall 13.4 9.4 1.48 (0.94–2.31) 1.53 (0.98–2.39)
Stratified by gender
Men 14.7 6.4 2.33 (1.11–4.89) 2.32 (1.10–4.88)
Women 12.3 11.8 1.09 (0.61–1.93) 1.14 (0.64–2.04)
Stratified by cumulative dosage prednisone equivalents within 6 months before baseline
67.5–134 DDDs 11.5 9.0 1.38 (0.66–2.89) 1.39 (0.66–2.93)
135–270 DDDs 13.8 8.3 1.61 (0.82–3.15) 1.60 (0.81–3.15)
>270 DDDs 17.9 14.0 1.77 (0.62–5.05) 1.74 (0.61–4.99)
Stratified by age categoryb
≤70 years 13.5 12.5 1.10 (0.61–1.98) 1.16 (0.64–2.09)
>70 years 13.4 6.5 2.14 (1.07–4.30) 2.22 (1.11–4.47)
OP osteoporosis prophylaxis drugs, HR hazard ratio, CI confidence interval, DDDs defined daily dosage prednisone equivalents
a Adjusted for age categories (≤70, >70) and use of hydrocortisone in the 6 months before baseline
bAdjusted for hydrocortisone use in the 6 months before baseline
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The major limitation of this study is that we do not know
how motivated the pharmacists were to perform the
intervention. It is likely that pharmacists did not notify all
GPs, but this has not been systematically registered. In
addition, we do not know if discussions between prescribers
and their patients about the start of GIOP took place. Possibly,
a number of approached patients refused to start osteoporosis
prophylaxis. Therefore, the actual effect of the pharmacist
intervention on the physician's behaviour may have been
greater than the reported effect. In addition, we had no clinical
data available such as (prior) BMD testing or the occurrence
of fractures (history). Guidelines recommend that pre-
menopausal women who use 7.5–15 mg of prednisone
equivalents for ≥3 months should receive a BMD
measurement. However, this study presumably included
post-menopausal women (≥50 years). Furthermore, we also
have included patients who were dispensed less than 135
DDD prednisone equivalents in the 6 months before baseline
(41.2 % in the control group, 37.9 % in the intervention
group), who were possibly not eligible for GIOP according
to the Dutch guideline. However, in the Netherlands, patients
are frequently dispensed medication for 3 months, and we
would have missed these patients if the inclusion period was
only 3 months before baseline. Moreover, all patients were
required to receive a dispensing for glucocorticoids within
3 months before baseline, and our results show that the
cumulative number of DDD prednisone equivalents did not
modify the intervention effect. Another limitation of this
study was that we were unable to exclude patients where
osteoporosis prophylaxis would have been contraindicated
or inappropriate (e.g. patients with serious cognitive or renal
impairment). Finally, this was a non-blinded RCTwith a lack
of clinical equipoise between the pharmacists in the
intervention group [27]. In other words, it is very likely that
all included pharmacists saw the importance of the intervention.
As a result, pharmacists could have been motivated to self-
identify patients other than those in the intervention group
who would also benefit from GIOP. This may have masked
the effect of the intervention.
The present study showed that simple feedback by
community pharmacists to physicians about patients eligible
for GIOP did not manage to significantly increase the
prescribing of bisphosphonates in the overall study
population. Subgroup analyses showed a significant increase
in males and in patients older than 70 years. However, the
absolute number of GIOP-treated patients remained low
which calls for more intensive pharmacy-based interventions.
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